(Q34775475)

4 August 2017

1 reference

title

Thalidomide and lenalidomide: Mechanism-based potential drug combinations (English)

1 reference

4 August 2017

0 references

2

Antonio Palumbo

1 reference

4 August 2017

5

Kenneth C Anderson

1 reference

4 August 2017

Sonia Vallet

1

1 reference

4 August 2017

Noopur Raje

series ordinal

3

1 reference

4 August 2017

Mario Boccadoro

series ordinal

4

1 reference

4 August 2017

language of work or name

1 reference

1 July 2008

1 reference

4 August 2017

1 reference

4 August 2017

49

1 reference

4 August 2017

1238-1245

1 reference

4 August 2017

7

1 reference

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

4 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

A short history of thalidomide embryopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide a promising new treatment for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Identification of genes downstream of Pax6 in the mouse lens using cDNA microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

New potential targets for treating myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Thalidomide causes platelet activation, which can be abrogated by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Risk of thrombosis with lenalidomide and its prevention with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

Activity of thalidomide in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802005191

10.1080/10428190802005191

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference